Amarin Corp Plc (AMRN)

[KCSVEN]

Excerpts from new EPA study:

https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-13-0257/_pdf


Taking all the findings into consideration, even when statin
treatment reduced the serum LDL-C level to <100mg/dl, there
was still an underlying residual risk of developing ACS in
patients with low serum EPA levels. It is possible that administration of EPA may reduce the residual risk of future cardiovascular events in patients who have received statin therapy
and have a mean LDL-C <100mg/dl.

We have shown in this study that low serum EPA and EPA+
DHA levels, but not the DHA level alone, were independently associated with coronary CTA findings, including the
extent of coronary plaques and their characteristics. Several
interventional studies have demonstrated that treatment with
EPA+DHA or EPA alone reduced the number of cardiac
events.7,8
Administration of DHA alone has not been reported
to do so.

Several studies have reported that the EPA/AA ratio is
associated with cardiac events36,37 because of the competition
between EPA and AA for enzymatic metabolism.25 Our present
study showed that the accuracy of the serum EPA level for
predicting NCPs was almost equal to that of the EPA/AA ratio
CONCLUSIONS
A low serum EPA level is associated with the presence and
extent of NCPs and the high-risk feature of LDPs with PR,
detected by coronary CTA, in patients with suspected or proven CAD who are undergoing statin treatment. These results
suggest that there is a residual risk of cardiovascular events in
patients receiving statin treatment. Administration of supplemental EPA may prevent plaque progression and alter plaque
characteristics.